Harmony Biosciences Holdings inc (NASDAQ: HRMY) |
|
Price: $39.0750
$1.24
3.264%
|
Day's High:
| $39.9
| Week Perf:
| 4.34 %
|
Day's Low: |
$ 37.95 |
30 Day Perf: |
7.29 % |
Volume (M): |
608 |
52 Wk High: |
$ 41.61 |
Volume (M$): |
$ 23,758 |
52 Wk Avg: |
$33.58 |
Open: |
$38.49 |
52 Wk Low: |
$28.14 |
|
|
Market Capitalization (Millions $) |
2,270 |
Shares
Outstanding (Millions) |
58 |
Employees |
246 |
Revenues (TTM) (Millions $) |
681 |
Net Income (TTM) (Millions $) |
123 |
Cash Flow (TTM) (Millions $) |
63 |
Capital Exp. (TTM) (Millions $) |
1 |
Harmony Biosciences Holdings Inc
Harmony Biosciences Holdings Inc is a clinical-stage biopharmaceutical company that was founded in 2017 and is headquartered in Plymouth Meeting, Pennsylvania. The company is focused on developing and commercializing innovative therapies for patients with sleep and central nervous system disorders.
Harmony Biosciences Holdings Inc is primarily known for its lead product, WAKIXe (pitolisant), which was approved by the U.S. Food and Drug Administration (FDA) in 2019 for the treatment of excessive daytime sleepiness or cataplexy in adult patients with narcolepsy. Narcolepsy is a chronic neurological disorder characterized by excessive daytime sleepiness, cataplexy, sleep paralysis, and hallucinations.
WAKIX represents a breakthrough in the treatment of narcolepsy as it works differently from existing treatments. It is a first-in-class medication that selectively targets the histamine 3 (H3) receptor, which is involved in the regulation of wakefulness and sleep. By activating this receptor, WAKIX increases histamine release in the brain, which helps to promote wakefulness.
Apart from WAKIX, Harmony Biosciences has a pipeline of other innovative compounds at various stages of development for central nervous system disorders. These include pitolisant, which is being evaluated for the treatment of patients with obstructive sleep apnea; and pitolisant-sodium oxybate, a combination therapy being developed for the treatment of narcolepsy.
Harmony Biosciences is also dedicated to bringing innovation and transformation to the field of sleep and central nervous system disorders. The company has a robust research and development program that is focused on identifying new molecular targets and developing new therapies to address unmet medical needs in the field.
In addition to developing innovative therapies, Harmony Biosciences is committed to improving the lives of patients with sleep and central nervous system disorders. The company collaborates with patient advocacy groups, healthcare professionals, and academic institutions to support research, education, and awareness of these disorders.
Company Address: 630 W. Plymouth Meeting 19462 PA
Company Phone Number: 539-9800 Stock Exchange / Ticker: NASDAQ HRMY
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Harmony Biosciences Holdings Inc
Harmony Biosciences Holdings Inc: A Resilient Player in the Pharmaceutical Market Despite some fluctuations in earnings per share (EPS) and net income, Harmony Biosciences Holdings Inc continues to showcase remarkable growth potential. The fiscal results for the period ending June 30, 2024, indicate a company not only in recovery but also strategically focused on delivering long-term value and growth. Solid Revenue Growth Amid Challenges In the latest fiscal announcements, Harmony Biosciences reported EPS of $0.20, which is down from $0.56 in the second quarter of 2023. Despite this decrease, the company achieved a notable 28.65% year-over-year surge in revenue, reaching $154.13 million. This growth trajectory indicates that while short-term profits may have dwindled, the company?s core product offerings resonate strongly within the market. Such revenue increase reflects growing demand for WAKIX (pitolisant), Harmony's flagship product for treating narcolepsy, a condition that affects a significant portion of the population. WAKIX itself achieved a net revenue of $172.8 million for the second quarter of 2024, demonstrating approximately 29% growth year-over-year. This success speaks volumes about the product's acceptance and its critical role in the company's offerings. With an increasing number of patients seeking effective treatments, WAKIX?s revenue performance builds a strong foundation for ongoing financial stability.
|
Harmony Biosciences Holdings Inc
Harmony Biosciences Holdings Inc, a prominent player in the Major Pharmaceutical Preparations sector, recently announced impressive financial results for the first quarter of the 2024 earnings season. With a remarkable 29.385% increase in revenue to $154.13 million and a soaring profit per share of 39.58% to $0.67 per share compared to the previous year, the company has undoubtedly demonstrated its strong growth and profitability. What sets Harmony Biosciences apart is its outstanding performance relative to its peers in the Major Pharmaceutical Preparations sector. While the average top-line elevation for two-thirds of the sector's entities was 4.96% from the first quarter of 2023, Harmony Biosciences outshone them all with its significant revenue growth. This achievement reaffirms the company's position as a leader in the industry.
|
Harmony Biosciences Holdings Inc
Harmony Biosciences Holdings Inc has once again proven itself to be a leader in the pharmaceutical industry with its recent financial report for the fourth quarter of 2023. Despite a decrease in earnings per share compared to the previous year, the company saw a significant increase in revenue, demonstrating a continued commitment to growth and success. One of the standout achievements from this report was the impressive revenue growth of 31.303%, far surpassing the industry average. This growth can be attributed to the company's focus on improving sales and meeting the demands of customers. Additionally, the increase in inventories and accounts receivable signal rising demand for Harmony Biosciences Holdings Inc's products, pointing towards a strong future for the company.
|
Dividend
Published Tue, Oct 31 2023 11:30 AM UTC
In the recently released press statement, Harmony Biosciences Holdings Inc reported impressive financial results for the third quarter of 2023. The company s flagship product, WAKIX (pitolisant), achieved a net revenue of $160.3 million during this period, representing a significant increase of approximately 37% compared to the same quarter last year. Despite these...
|
Harmony Biosciences Holdings Inc
Article: Harmony Biosciences Faces Challenges as Earnings Decline, but Revenue Rises Harmony Biosciences Holdings Inc, a Major Pharmaceutical Preparations company, recently announced its financial results for the period of July to September 30, 2023. While the company saw a decline in earnings per share (EPS), it experienced an impressive rise in revenue. These results have significant implications for the company's future performance. During the third quarter of 2023, Harmony Biosciences Holdings Inc reported earnings per share of $0.63 and revenue of $134.22 million. This represented a significant drop in EPS from $1.44 per share in the corresponding period the previous year. However, despite the decline in EPS, the company's revenue increased by a notable 36.488% in the same period. This revenue growth stands in contrast to the downward trend seen in many of its competitors in the Major Pharmaceutical Preparations industry during the matching period.
|
Per Share |
Current |
Earnings (TTM) |
2.12 $ |
Revenues (TTM) |
11.71 $
|
Cash Flow (TTM) |
1.08 $ |
Cash |
7.06 $
|
Book Value |
10.27 $
|
Dividend (TTM) |
0 $ |
|
Per Share |
|
Earnings (TTM) |
2.12 $
|
Revenues (TTM) |
11.71 $ |
Cash Flow (TTM) |
1.08 $ |
Cash |
7.06 $
|
Book Value |
10.27 $ |
Dividend (TTM) |
0 $ |
|
|
|
|